| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
11-Azidoundecanoic acid does not have a specific biological target; rather, it is a chemical tool used for bioconjugation and labeling applications. The azide group serves as a bioorthogonal handle for selective conjugation to alkyne-functionalized molecules via click chemistry. The carboxylic acid group can be activated for conjugation to primary amines on proteins, peptides, or other biomolecules, enabling the attachment of the azide handle to biological targets for subsequent labeling or modification. Its primary "target" is the chemical functionality of alkyne-containing molecules in click chemistry reactions.
|
|---|---|
| ln Vitro |
On a designed LplA acceptor peptide (LAP), the microbial lipoic acid ligase LplA has the ability to selectively bind an alkyl azide. Subsequently, the alkyl azide preferentially transforms into cyclooctyne conjugates for a range of probes[1]. Using tiny fluorophores provided by means of a brief peptide tag, the LplA approach could enable widespread access to biochemical and imaging studies of cell surface proteins[1].
In vitro activity of 11-Azidoundecanoic acid is assessed by its efficiency as a click chemistry reagent and bioconjugation linker. The compound is used to functionalize surfaces, nanoparticles, or biomolecules with azide groups. Its reactivity in CuAAC reactions is typically evaluated using model alkyne compounds, with reaction progress monitored by HPLC, LC-MS, or fluorescence if a labeled alkyne is used. The compound's ability to serve as a hydrophobic linker is demonstrated by its incorporation into lipid-based delivery systems or membrane-anchoring applications. Its in vitro utility is measured by conjugation efficiency and the stability of the resulting conjugates under physiological conditions. |
| ln Vivo |
In vivo applications of 11-Azidoundecanoic acid are primarily related to its use in bioorthogonal labeling and drug delivery. The compound can be incorporated into lipid-based formulations or conjugated to therapeutics for in vivo imaging or targeted delivery. Its hydrophobic nature may facilitate incorporation into cell membranes or lipid nanoparticles. However, detailed in vivo activity data are limited as the compound is primarily a chemical reagent rather than a therapeutic agent. In vivo click chemistry applications may involve pre-targeting strategies where azide-modified antibodies or nanoparticles are administered, followed by injection of labeled alkynes for imaging or therapy.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable for 11-Azidoundecanoic acid as it is not a drug targeting biological macromolecules. Instead, its chemical reactivity is assessed using model conjugation reactions. Typical protocols involve mixing the compound with an alkyne-functionalized molecule in the presence of a copper catalyst and a reducing agent (e.g., sodium ascorbate) at room temperature or 37degC. Reaction progress is monitored by TLC, HPLC, or mass spectrometry. Conjugation efficiency is calculated by comparing the relative amounts of starting materials and products. The compound's stability in various buffers and solvents is also assessed to determine optimal reaction conditions.
|
| Cell Assay |
Cellular assays for 11-Azidoundecanoic acid involve evaluating its incorporation into cellular components or its utility for cell surface labeling. Cells are incubated with azide-modified lipids or azide-functionalized molecules derived from 11-Azidoundecanoic acid. Incorporation is detected by subsequent reaction with fluorescently labeled alkynes via click chemistry, followed by flow cytometry or fluorescence microscopy. Cytotoxicity of the compound or its conjugates is assessed using standard cell viability assays such as MTT or LDH release. The compound's ability to label specific cellular targets is evaluated by comparing fluorescence signals in treated versus control cells.
|
| Animal Protocol |
In vivo animal studies for 11-Azidoundecanoic acid are limited, as the compound is primarily a chemical reagent rather than a therapeutic agent. When used in vivo, the compound is typically administered as part of a pre-targeting strategy for imaging or drug delivery. Animal models (mice or rats) may be injected with azide-modified antibodies or nanoparticles, followed by administration of labeled alkynes for bioorthogonal labeling. Tissue distribution and labeling efficiency are assessed by imaging or tissue analysis. The compound may also be used to study fatty acid metabolism or lipid biology in animal models, though such applications are less commonly reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 11-Azidoundecanoic acid are characteristic of medium-chain fatty acids. The compound has a molecular weight of 227.30 g/mol and is lipophilic due to its 11-carbon hydrophobic chain. The azide group and carboxylic acid provide sites for chemical modification. The compound is soluble in organic solvents and can be formulated for in vivo administration using appropriate carriers such as DMSO or lipid-based formulations. Its pharmacokinetic properties are highly dependent on the formulation and the specific conjugate to which it is attached. Detailed PK data are not extensively reported for this reagent.
|
| Toxicity/Toxicokinetics |
Toxicological data for 11-Azidoundecanoic acid are limited, as the compound is used primarily as a chemical reagent in research applications. The compound contains an azide group, which can be potentially explosive and should be handled with caution. It is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for labeling (typically 1-100 microM). Toxicity may arise from the azide group or the fatty acid chain at high concentrations. Standard safety precautions include avoiding heat, shock, friction, and contact with reducing agents that may decompose the azide group.
|
| References |
[1]. Fernández-Suárez M, et al. Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule probes. Nat Biotechnol. 2007 Dec;25(12):1483-7.
[2]. Heal WP, et al. N-Myristoyl transferase-mediated protein labelling in vivo. Org Biomol Chem. 2008 Jul 7;6(13):2308-15. |
| Additional Infomation |
11-Azidoundecanoic acid is a versatile click chemistry reagent and hydrophobic bioconjugation linker widely used in chemical biology and materials science. Its applications include bioconjugation, surface modification, drug delivery systems, and the creation of azide-functionalized surfaces or biomolecule tagging. The compound is compatible with copper-catalyzed azide-alkyne cycloaddition (CuAAC) and Staudinger ligation. It is available in high purity (≥95%) and is typically stored at room temperature. The compound is not an FDA-approved drug and has no clinical indications.
|
| Molecular Formula |
C11H21N3O2
|
|---|---|
| Molecular Weight |
227.30
|
| Exact Mass |
227.163
|
| CAS # |
118162-45-1
|
| PubChem CID |
454094
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.344
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
16
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N=[N+]=[N-])=O
|
| InChi Key |
LXAVFOAOGZWQKT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H21N3O2/c12-14-13-10-8-6-4-2-1-3-5-7-9-11(15)16/h1-10H2,(H,15,16)
|
| Chemical Name |
11-azidoundecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (439.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.00 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3995 mL | 21.9974 mL | 43.9947 mL | |
| 5 mM | 0.8799 mL | 4.3995 mL | 8.7989 mL | |
| 10 mM | 0.4399 mL | 2.1997 mL | 4.3995 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
